Celyad Oncology SA (CYAD.BR)

EUR 0.47

(0.65%)

Revenue Summary of Celyad Oncology SA

Celyad Oncology SA's latest annual revenue in 2023 was 102 Thousand EUR , down 0.0% from previous year.
Celyad Oncology SA's latest quarterly revenue in 2024 Q2 was 14 Thousand EUR , down 0.0% from previous quarter.
Celyad Oncology SA reported a annual revenue of - EUR in annual revenue 2022, down 0.0% from previous year.
Celyad Oncology SA reported a annual revenue of - EUR in annual revenue 2021, down -100.0% from previous year.
Celyad Oncology SA reported a quarterly revenue of 102 Thousand EUR for 2023 FY, down 0.0% from previous quarter.
Celyad Oncology SA reported a quarterly revenue of 58 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Revenue Chart of Celyad Oncology SA (2023 - 2011)

Historical Annual Revenue of Celyad Oncology SA (2023 - 2011)

Year	Revenue	Revenue Growth
2023	102 Thousand EUR	0.0%
2022	- EUR	0.0%
2021	- EUR	-100.0%
2020	5000.00 EUR	-16.67%
2019	6000.00 EUR	-99.81%
2018	3.11 Million EUR	-12.01%
2017	3.54 Million EUR	-58.47%
2016	8.52 Million EUR	284000.0%
2015	3000.00 EUR	-97.95%
2014	146 Thousand EUR	0.0%
2013	- EUR	-100.0%
2012	54 Thousand EUR	100.5%
2011	26.93 Thousand EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	14 Thousand EUR	0.0%
2023 FY	102 Thousand EUR	0.0%
2023 Q4	58 Thousand EUR	0.0%
2023 Q2	44 Thousand EUR	0.0%
2022 FY	- EUR	0.0%
2022 Q4	- EUR	0.0%
2022 Q2	- EUR	0.0%
2022 Q1	- EUR	0.0%
2021 Q2	- EUR	0.0%
2021 Q4	- EUR	0.0%
2021 FY	- EUR	-100.0%
2021 Q1	- EUR	0.0%
2021 Q3	- EUR	0.0%
2020 FY	5000.00 EUR	-16.67%
2020 Q3	- EUR	-100.0%
2020 Q4	- EUR	0.0%
2020 Q2	5000.00 EUR	0.0%
2019 Q2	1500.00 EUR	0.0%
2019 FY	6000.00 EUR	-99.81%
2019 Q4	6000.00 EUR	0.0%
2019 Q1	1500.00 EUR	-99.75%
2018 Q2	2.51 Million EUR	223.34%
2018 Q1	778.75 Thousand EUR	2125.0%
2018 FY	3.11 Million EUR	-12.01%
2018 Q4	597 Thousand EUR	0.0%
2017 Q2	3.5 Million EUR	296.05%
2017 FY	3.54 Million EUR	-58.47%
2017 Q4	35 Thousand EUR	0.0%
2017 Q1	885 Thousand EUR	-89.57%
2016 Q4	8.48 Million EUR	0.0%
2016 FY	8.52 Million EUR	284000.0%
2016 Q2	40 Thousand EUR	-98.12%
2016 Q1	2.13 Million EUR	70925.0%
2015 Q4	3000.00 EUR	300.0%
2015 FY	3000.00 EUR	-97.95%
2015 Q3	750.00 EUR	0.0%
2015 Q2	750.00 EUR	0.0%
2015 Q1	750.00 EUR	-99.49%
2014 Q1	36.5 Thousand EUR	0.0%
2014 FY	146 Thousand EUR	0.0%
2014 Q4	146 Thousand EUR	300.0%
2014 Q3	36.5 Thousand EUR	0.0%
2014 Q2	36.5 Thousand EUR	0.0%
2013 Q3	- EUR	0.0%
2013 Q4	36.5 Thousand EUR	0.0%
2013 FY	- EUR	-100.0%
2013 Q1	- EUR	0.0%
2013 Q2	- EUR	0.0%
2012 Q2	13.5 Thousand EUR	0.0%
2012 FY	54 Thousand EUR	100.5%
2012 Q1	13.5 Thousand EUR	0.0%
2012 Q3	13.5 Thousand EUR	0.0%
2012 Q4	- EUR	-100.0%
2011 Q4	13.5 Thousand EUR	100.5%
2011 Q1	6733.02 EUR	0.0%
2011 Q2	6733.02 EUR	0.0%
2011 Q3	6733.02 EUR	0.0%
2011 FY	26.93 Thousand EUR	0.0%
2010 Q4	6733.02 EUR	0.0%

Peer Revenue Comparison of Celyad Oncology SA

Name	Revenue	Revenue Difference
Nicox S.A.	257 Thousand EUR	60.311%
European Medical Solutions	40.56 Million EUR	99.749%
FERMENTALG	4.05 Million EUR	97.486%
argenx SE	1.13 Billion EUR	99.991%
BioSenic S.A.	543 Thousand EUR	81.215%
Hyloris Pharmaceuticals SA	2.08 Million EUR	95.113%
Onward Medical N.V.	532 Thousand EUR	80.827%
Oxurion NV	263 Thousand EUR	61.217%
PHAXIAM Therapeutics S.A.	1.32 Million EUR	92.308%
Financière de Tubize SA	- EUR	-Infinity%
UCB SA	5.25 Billion EUR	99.998%